
June 18 (Reuters) - Zealand Pharma A/S ZELA.CO:
ZEALAND PHARMA ANNOUNCES POSITIVE TOPLINE RESULTS FROM 28-WEEK PHASE 1B TRIAL WITH GLP-1/GLP-2 RECEPTOR DUAL AGONIST DAPIGLUTIDE
ZEALAND PHARMA A/S - MEAN BODY WEIGHT REDUCTION OF 11.6% AFTER 28 WEEKS WITH DAPIGLUTIDE
ZEALAND PHARMA A/S - DAPIGLUTIDE TREATMENT ASSESSED TO BE SAFE AND WELL-TOLERATED
ZEALAND PHARMA A/S - HIGHER DOSES OF DAPIGLUTIDE ASSESSED TO BE SAFE AND WELL-TOLERATED